Published in Front Neurosci on April 25, 2017
Nutritional Supplements and Performance During Visual Field Testing (B3 Vitamin) | NCT03797469
The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol (2006) 25.47
Protein import into mitochondria. Annu Rev Biochem (1997) 6.82
Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene. Nat Neurosci (2001) 4.10
Molecular characterization and comparison of the components and multiprotein complexes in the postsynaptic proteome. J Neurochem (2006) 3.67
Essential iris atrophy, pigment dispersion, and glaucoma in DBA/2J mice. Invest Ophthalmol Vis Sci (1998) 3.61
New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol (2012) 3.45
Axons of retinal ganglion cells are insulted in the optic nerve early in DBA/2J glaucoma. J Cell Biol (2007) 3.45
Absence of Wallerian Degeneration does not Hinder Regeneration in Peripheral Nerve. Eur J Neurosci (1989) 3.24
Wallerian degeneration, wld(s), and nmnat. Annu Rev Neurosci (2010) 3.22
Wlds protection distinguishes axon degeneration following injury from naturally occurring developmental pruning. Neuron (2006) 3.15
Inherited glaucoma in DBA/2J mice: pertinent disease features for studying the neurodegeneration. Vis Neurosci (2005) 2.86
Drosophila NMNAT maintains neural integrity independent of its NAD synthesis activity. PLoS Biol (2006) 2.70
Susceptibility to neurodegeneration in a glaucoma is modified by Bax gene dosage. PLoS Genet (2005) 2.68
A local mechanism mediates NAD-dependent protection of axon degeneration. J Cell Biol (2005) 2.64
Interacting loci cause severe iris atrophy and glaucoma in DBA/2J mice. Nat Genet (1999) 2.30
Molecular clustering identifies complement and endothelin induction as early events in a mouse model of glaucoma. J Clin Invest (2011) 2.25
Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice. Science (2017) 2.06
NAD synthase NMNAT acts as a chaperone to protect against neurodegeneration. Nature (2008) 2.01
Intraocular pressure in genetically distinct mice: an update and strain survey. BMC Genet (2001) 1.88
Intraocular pressure in inbred mouse strains. Invest Ophthalmol Vis Sci (1997) 1.83
Glaucoma: thinking in new ways-a rôle for autonomous axonal self-destruction and other compartmentalised processes? Prog Retin Eye Res (2005) 1.83
Early microglia activation in a mouse model of chronic glaucoma. J Comp Neurol (2011) 1.69
Transgenic mice expressing the Nmnat1 protein manifest robust delay in axonal degeneration in vivo. J Neurosci (2009) 1.69
Under pressure: cellular and molecular responses during glaucoma, a common neurodegeneration with axonopathy. Annu Rev Neurosci (2012) 1.65
Neurites can remain viable after destruction of the neuronal soma by programmed cell death (apoptosis). Dev Biol (1994) 1.59
WldS prevents axon degeneration through increased mitochondrial flux and enhanced mitochondrial Ca2+ buffering. Curr Biol (2012) 1.55
Semaphorin function in neural plasticity and disease. Curr Opin Neurobiol (2009) 1.48
Non-nuclear Wld(S) determines its neuroprotective efficacy for axons and synapses in vivo. J Neurosci (2009) 1.46
The WldS gene delays axonal but not somatic degeneration in a rat glaucoma model. Eur J Neurosci (2008) 1.43
Deletion of the ryanodine receptor type 3 (RyR3) impairs forms of synaptic plasticity and spatial learning. EMBO J (1999) 1.42
A rat model of slow Wallerian degeneration (WldS) with improved preservation of neuromuscular synapses. Eur J Neurosci (2005) 1.39
Delayed synaptic degeneration in the CNS of Wlds mice after cortical lesion. Brain (2006) 1.20
Expression of the growth-associated protein GAP-43 in adult rat retinal ganglion cells following axon injury. Neuron (1991) 1.14
A role for semaphorin 3A signaling in the degeneration of hippocampal neurons during Alzheimer's disease. J Neurochem (2004) 1.04
Mislocalization of neuronal mitochondria reveals regulation of Wallerian degeneration and NMNAT/WLD(S)-mediated axon protection independent of axonal mitochondria. Hum Mol Genet (2013) 1.01
Retinal ganglion cell dendritic atrophy in DBA/2J glaucoma. PLoS One (2013) 0.99
Opa1 is essential for retinal ganglion cell synaptic architecture and connectivity. Brain (2012) 0.97
Anti-semaphorin 3A antibodies rescue retinal ganglion cells from cell death following optic nerve axotomy. J Biol Chem (2002) 0.96
Nicotinamide inhibits cyclic ADP-ribose-mediated calcium signalling in sea urchin eggs. Biochem J (1996) 0.95
LKB1 and AMPK regulate synaptic remodeling in old age. Nat Neurosci (2014) 0.95
WldS and PGC-1α regulate mitochondrial transport and oxidation state after axonal injury. J Neurosci (2013) 0.93
Inhibition of cADP-ribose formation produces vasodilation in bovine coronary arteries. Hypertension (2000) 0.93
Robust mouse pattern electroretinograms derived simultaneously from each eye using a common snout electrode. Invest Ophthalmol Vis Sci (2014) 0.92
SEMA4D compromises blood-brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease. Neurobiol Dis (2014) 0.91
Metabotropic glutamate receptors and neurodegenerative diseases. Pharmacol Res (2016) 0.90
Eph receptors at synapses: implications in neurodegenerative diseases. Cell Signal (2011) 0.89
WldS but not Nmnat1 protects dopaminergic neurites from MPP+ neurotoxicity. Mol Neurodegener (2012) 0.89
Inhibition of the classical pathway of the complement cascade prevents early dendritic and synaptic degeneration in glaucoma. Mol Neurodegener (2016) 0.87
Electrophysiological assessment of retinal ganglion cell function. Exp Eye Res (2015) 0.86
Axon degeneration and PGC-1α-mediated protection in a zebrafish model of α-synuclein toxicity. Dis Model Mech (2014) 0.86
WldS enhances insulin transcription and secretion via a SIRT1-dependent pathway and improves glucose homeostasis. Diabetes (2011) 0.84
Ryanodine receptors: physiological function and deregulation in Alzheimer disease. Mol Neurodegener (2014) 0.82
Differential expression of sema3A and sema7A in a murine model of multiple sclerosis: Implications for a therapeutic design. Clin Immunol (2015) 0.77